Type II DNA topoisomerase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Type II DNA topoisomerase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Type II DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Type II DNA topoisomerase inhibitors: Overview
Type II topoisomerases are ubiquitous enzymes that play an essential role in the control of replicative DNA synthesis and share structural and functional homology among different prokaryotic and eukaryotic organisms. Small molecules that target type II topoisomerase are divided into two classes: inhibitors and poisons. Due to their frequent presence in proliferating eukaryotic cells, inhibitors of type II topoisomerases have been extensively studied and used as anti-cancer medications.
Report Highlights
This segment of the Type II DNA topoisomerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type II DNA topoisomerase inhibitors Emerging Drugs
Further product details are provided in the report……..
Type II DNA topoisomerase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Type II DNA topoisomerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Type II DNA topoisomerase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type II DNA topoisomerase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type II DNA topoisomerase inhibitors drugs.
Type II DNA topoisomerase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Type II DNA topoisomerase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Type II DNA topoisomerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Type II DNA topoisomerase inhibitors: Overview
Type II topoisomerases are ubiquitous enzymes that play an essential role in the control of replicative DNA synthesis and share structural and functional homology among different prokaryotic and eukaryotic organisms. Small molecules that target type II topoisomerase are divided into two classes: inhibitors and poisons. Due to their frequent presence in proliferating eukaryotic cells, inhibitors of type II topoisomerases have been extensively studied and used as anti-cancer medications.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Type II DNA topoisomerase inhibitors R&D. The therapies under development are focused on novel approaches for Type II DNA topoisomerase inhibitors.
This segment of the Type II DNA topoisomerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Type II DNA topoisomerase inhibitors Emerging Drugs
- TRP-1001: Tryp Therapeutics
- Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology
Further product details are provided in the report……..
Type II DNA topoisomerase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Type II DNA topoisomerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Type II DNA topoisomerase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Type II DNA topoisomerase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type II DNA topoisomerase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type II DNA topoisomerase inhibitors drugs.
Type II DNA topoisomerase inhibitors Report Insights
- Type II DNA topoisomerase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Type II DNA topoisomerase inhibitors drugs?
- How many Type II DNA topoisomerase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type II DNA topoisomerase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type II DNA topoisomerase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Type II DNA topoisomerase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tryp Therapeutics
- CSPC ZhongQi Pharmaceutical Technology
- Oasmia Pharmaceutical
- Aradigm
- Teclison
- Denovo Biopharma
- NanoCarrier
- EnGeneIC
- Avacta
- Shasqi
- SkinJect
- Lantern Pharma
- Double Bond Pharmaceutical
- POP Biotechnologies
- LIDDS
- TenNor Therapeutics
- Exelixis
- EnGeneIC
- TRP-1001
- Mitoxantrone liposomal
- Doxophos
- Apulmiq
- Tirazone
- DB 106
- NC 6003
- VEDVDox
- AVA 6000
- SQ 3370
- Doxorubicin-containing MNA
- LP 184
- SA 033
- Doxorubicin/Porphyrin phospholipid nanoparticles
- NZ DOX
- PNU-159682 based antibody drug conjugate
- E-EDV-D682
Introduction
Executive Summary
Type II DNA topoisomerase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Type II DNA topoisomerase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TRP-1001: Tryp Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
NC 6003: NanoCarrier
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NZ DOX: LIDDS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type II DNA topoisomerase inhibitors Key Companies
Type II DNA topoisomerase inhibitors Key Products
Type II DNA topoisomerase inhibitors- Unmet Needs
Type II DNA topoisomerase inhibitors- Market Drivers and Barriers
Type II DNA topoisomerase inhibitors- Future Perspectives and Conclusion
Type II DNA topoisomerase inhibitors Analyst Views
Type II DNA topoisomerase inhibitors Key Companies
Appendix
Executive Summary
Type II DNA topoisomerase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Type II DNA topoisomerase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TRP-1001: Tryp Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
NC 6003: NanoCarrier
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
NZ DOX: LIDDS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Type II DNA topoisomerase inhibitors Key Companies
Type II DNA topoisomerase inhibitors Key Products
Type II DNA topoisomerase inhibitors- Unmet Needs
Type II DNA topoisomerase inhibitors- Market Drivers and Barriers
Type II DNA topoisomerase inhibitors- Future Perspectives and Conclusion
Type II DNA topoisomerase inhibitors Analyst Views
Type II DNA topoisomerase inhibitors Key Companies
Appendix